论文部分内容阅读
1研发c-Met抑制剂—从苗头到先导化合物1.1 c-Met是抗肿瘤药物的靶标辉瑞公司于2006年上市了舒尼替尼(1,sunitinib),由于1对多种酪氨酸激酶(VEGFR、PDGFR和KIT)的抑制作用,得以治疗对伊马替尼耐药的胃肠道间质瘤(GIST)患者。循此研发路径,公司也着手研究与肿瘤相关的其他激酶的药物。
1 R & D c-Met inhibitors - from vaccine to lead compounds 1.1 c-Met is the target of anti-cancer drugs Pfizer listed sunitinib in 2006 as one of several pairs of tyrosine kinases VEGFR, PDGFR and KIT) to treat patients with gastrointestinal stromal tumors (GIST) resistant to imatinib. Following this R & D path, the company is also investigating drugs that target other tumor-associated kinases.